Evidence map›Paper›PMID 35695802›Full record

ArticleBrain pathology (Zurich, Switzerland)2022

Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease.

Jessica Lisa Littau, Lina Velilla, Yoshiki Hase, Nelson David Villalba-Moreno, Christian Hagel, Dagmar Drexler, Santiago Osorio Restrepo, Andres Villegas, Francisco Lopera, Sergio Vargas and 6 more

Open access · goldAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Jessica Lisa LittauInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Lina VelillaNeuroscience Group of Antioquia, University of Antioquia, Medellín.
Yoshiki HaseNeurovascular Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne.
Nelson David Villalba-MorenoInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian HagelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dagmar DrexlerInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Santiago Osorio RestrepoDepartment of Radiology, Neuroradiology Section, Universidad de Antioquia, Medellín, Colombia.
Andres VillegasNeuroscience Group of Antioquia, University of Antioquia, Medellín.
Francisco LoperaNeuroscience Group of Antioquia, University of Antioquia, Medellín.
Sergio VargasDepartment of Radiology, Neuroradiology Section, Universidad de Antioquia, Medellín, Colombia.
Markus GlatzelInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Susanne KrasemannInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Yakeel T QuirozMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Joseph F Arboleda-VelasquezSchepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, Massachusetts.
Rajesh KalariaNeurovascular Research Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne.ORCID 0000-0001-7907-4923
Diego Sepulveda-FallaInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0003-0176-2042
Universität Hamburg · DEUniversidad de Antioquia · COClinical Research Institute · USHarvard University · USMassachusetts Eye and Ear Infirmary · US

Funding

Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASILRF1NS110048 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH, SEPULVEDA-FALLA, DIEGO · 2018 to 2019
$3.6M
Medical Research Council G1100540NINDS NIH HHS RF1 NS110048The Dunhill Medical Trust R277/0213
6 · The paper itself

Abstract

We studied small vessel disease (SVD) pathology in Familial Alzheimer's disease (FAD) subjects carrying the presenilin 1 (PSEN1) p.Glu280Ala mutation in comparison to those with sporadic Alzheimer's disease (SAD) as a positive control for Alzheimer's pathology and Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) bearing different NOTCH3 mutations, as positive controls for SVD pathology. Upon magnetic resonance imaging (MRI) in life, some FAD showed mild white matter hyperintensities and no further radiologic evidence of SVD. In post-mortem studies, total SVD pathology in cortical areas and basal ganglia was similar in PSEN1 FAD and CADASIL subjects, except for the feature of arteriosclerosis which was higher in CADASIL subjects than in PSEN1 FAD subjects. Further only a few SAD subjects showed a similar degree of SVD pathology as observed in CADASIL. Furthermore, we found significantly enlarged perivascular spaces in vessels devoid of cerebral amyloid angiopathy in FAD compared with SAD and CADASIL subjects. As expected, there was greater fibrinogen-positive perivascular reactivity in CADASIL but similar reactivity in PSEN1 FAD and SAD groups. Fibrinogen immunoreactivity correlated with onset age in the PSEN1 FAD cases, suggesting increased vascular permeability may contribute to cognitive decline. Additionally, we found reduced perivascular expression of PDGFRβ AQP4 in microvessels with enlarged PVS in PSEN1 FAD cases. We demonstrate that there is Aβ-independent SVD pathology in PSEN1 FAD, that was marginally lower than that in CADASIL subjects although not evident by MRI. These observations suggest presence of covert SVD even in PSEN1, contributing to disease progression. As is the case in SAD, these consequences may be preventable by early recognition and actively controlling vascular disease risk, even in familial forms of dementia.

Indexed as

Alzheimer DiseaseCADASILAmyloid beta-PeptidesFibrinogenHumansAmyloid beta-PeptidesFibrinogenAlzheimer's diseasecerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathydementiaFADpresenilinsmall vessel diseasevascular disease

Identifiers

PMID35695802
PMCPMC9616091
OpenAlexW4282555638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.